{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-165205","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:31.945388+00:00","generated_at":"2026-05-15T05:03:02.249675+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.3,"confidence":"high","headline":"Plus Therapeutics regains Nasdaq minimum bid price compliance after 1-for-25 reverse split","bullets":["Nasdaq notified Plus Therapeutics on April 20, 2026 that bid price closed at or above $1.00 for 10 consecutive days through April 17.","Reverse stock split (1-for-25) was effective April 2, 2026 and enabled compliance with Listing Rule 5550(a)(2).","Nasdaq has closed the matter; PSTV common stock remains listed on The Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-165205","json":"https://secwatch.observer/filing/0001193125-26-165205.json","markdown":"https://secwatch.observer/filing/0001193125-26-165205.md","text":"https://secwatch.observer/filing/0001193125-26-165205.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526165205/0001193125-26-165205-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000119312526165205/pstv-20260420.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:03:02.249675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}